LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast
- PMID: 9781650
- DOI: 10.1016/s0046-8177(98)90422-1
LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast
Abstract
Papillary carcinoma of the breast is a variant of predominantly intraductal carcinoma characterized by a papillary growth pattern with fibrovascular support. Loss of heterozygosity (LOH) was evaluated at multiple chromosomal loci (including loci reported to show frequent genetic alterations in breast cancer) to determine the frequency of genetic mutations in these tumors and their precursors. Thirty-three papillary lesions of the breast (6 papillary carcinomas, 12 carcinomas arising in a papilloma, and 15 intraductal papillomas with florid epithelial hyperplasia) were retrieved from the files of the Armed Forces Institute of Pathology (AFIP). Tumor cells and normal tissue were microdissected in each case and screened for LOH at INT-2 and p53 as well as several loci on chromosome 16p13 in the TSC2/PKD1 gene region (D16S423, D16S663, D16S665). LOH on chromosome 16p13 was present in 10 of 16 (63%) informative cases of either papillary carcinoma or carcinoma arising in a papilloma as well as in 6 of 10 (60%) informative cases of intraductal papilloma with florid epithelial hyperplasia (IDH). One case showed simultaneous LOH in both the florid IDH and carcinoma components of a papilloma. LOH was not observed at either INT-2 or p53 in any of the papillary carcinomas or papillomas with florid IDH. In conclusion, a high frequency of LOH at chromosome 16p13 (the TSC2/PKD1 gene region) is in both papillary carcinomas of the breast as well as in papillomas with florid IDH, including a case with LOH present simultaneously in both components. These findings suggest that chromosome 16p contains a tumor suppressor gene that frequently is mutated early in papillary neoplasia.
Similar articles
-
Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.Mod Pathol. 1999 Dec;12(12):1083-9. Mod Pathol. 1999. PMID: 10619258
-
Papillary lesions of the breast: a molecular progression?Breast Cancer Res Treat. 2005 Mar;90(1):71-6. doi: 10.1007/s10549-004-3003-3. Breast Cancer Res Treat. 2005. PMID: 15770529
-
Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade.Clin Cancer Res. 1995 Mar;1(3):261-7. Clin Cancer Res. 1995. PMID: 9815981
-
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.Adv Exp Med Biol. 1997;407:41-53. doi: 10.1007/978-1-4899-1813-0_7. Adv Exp Med Biol. 1997. PMID: 9321930 Review.
-
Genetic alterations in presumptive precursor lesions of breast carcinomas.Anal Cell Pathol. 2002;24(2-3):69-76. doi: 10.1155/2002/371680. Anal Cell Pathol. 2002. PMID: 12446956 Free PMC article. Review.
Cited by
-
Intracystic papillary carcinoma of breast: interrelationship with in situ and invasive carcinoma and a proposal of pathogenesis: array comparative genomic hybridization study of 14 cases.Mod Pathol. 2014 Feb;27(2):194-203. doi: 10.1038/modpathol.2013.136. Epub 2013 Aug 2. Mod Pathol. 2014. PMID: 23907150 Free PMC article.
-
Pan-cancer analysis of whole-genome doubling and its association with patient prognosis.BMC Cancer. 2023 Jul 3;23(1):619. doi: 10.1186/s12885-023-11132-6. BMC Cancer. 2023. PMID: 37400777 Free PMC article.
-
Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.Am J Respir Crit Care Med. 2015 Feb 1;191(3):352-5. doi: 10.1164/rccm.201408-1480LE. Am J Respir Crit Care Med. 2015. PMID: 25635494 Free PMC article. No abstract available.
-
Papillary neoplasms of the breast-reviewing the spectrum.Mod Pathol. 2021 Jun;34(6):1044-1061. doi: 10.1038/s41379-020-00732-3. Epub 2021 Jan 18. Mod Pathol. 2021. PMID: 33462367 Review.
-
Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway.Cell Cycle. 2009 May 1;8(9):1344-51. doi: 10.4161/cc.8.9.8215. Epub 2009 May 18. Cell Cycle. 2009. PMID: 19342893 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous